Recursion Pharmaceuticals (NasdaqGS:RXRX) reported a 10% decline in its share price last week as it announced first-quarter 2025 results with an increased net loss despite rising sales and revenue.

Shares of Recursion Pharmaceuticals (RXRX 5.04%) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.You can reach Elaine on Signal at elaineywchen.70.

Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts giving analysts, investors ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence ...

Recursion trumpeted the results as if they were successful, but this program isn't going anywhere fast. The company still hasn't announced plans to launch a phase 3 study for REC-994, the ...

Altitude Lab, a biotech accelerator formed by Recursion, on Wednesday announced the launch of a pre-seed venture fund to support early-stage startups affected by the changes in federal funding policy.

The ecosystem around Python is massive. There is a rich set of libraries and frameworks that are specifically designed for AI and ML, including TensorFlow, PyTorch, Keras, Scikit-learn, and Pandas ...

For October 2024, Python continues to reign as the most popular programming language, growing by +7.08 percent in the past month and holding a 21.90 percent market share.